SEC Form 4 · accession 0001209191-15-067634
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carol Giltner Gallagher
Director
Period of report
Aug 20, 2015
Accepted (ET)
Aug 24, 2015 · 7:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 20, 2015 | S | 2,000 | $43.24 | D | 107,538 | D | |
| Common StockF3 | Aug 20, 2015 | S | 600 | $44.08 | D | 106,938 | D | |
| Common StockF4 | Aug 20, 2015 | S | 3,274 | $45.88 | D | 103,664 | D | |
| Common StockF5 | Aug 21, 2015 | S | 5,426 | $41.65 | D | 98,238 | D | |
| Common StockF6 | Aug 21, 2015 | S | 448 | $42.46 | D | 97,790 | D | |
| Common StockF7 | Aug 24, 2015 | S | 627 | $38.44 | D | 97,163 | D | |
| Common StockF8 | Aug 24, 2015 | S | 1,232 | $39.77 | D | 95,931 | D | |
| Common StockF9 | Aug 24, 2015 | S | 2,736 | $40.67 | D | 93,195 | D | |
| Common StockF10 | Aug 24, 2015 | S | 1,279 | $41.88 | D | 91,916 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted May 22, 2015.
- F10The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.61 to $42.29. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.71 to $43.62. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.00 to $44.125. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.53 to $46.44. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.15 to $42.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.21 to $42.66. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.00 to $38.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.50 to $40.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.505 to $41.39. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.